About Nucleonics
Nucleonics is a company based in Langhorne (United States) founded in 2001 was acquired by Alnylam in December 2008. Nucleonics has raised $51.9 million across 3 funding rounds from investors including Alnylam, Oxford Finance and Burrill and Company. Nucleonics offers products and services including Hepatitis B Therapeutic Program, Hepatitis C Therapeutic Program, and DNA Delivery Technology. Nucleonics operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Denali Therapeutics, MiRagen and Avidity Biosciences, among others.
- Headquarter Langhorne, United States
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Nucleonics Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nucleonics
Nucleonics offers a comprehensive portfolio of products and services, including Hepatitis B Therapeutic Program, Hepatitis C Therapeutic Program, and DNA Delivery Technology.
RNAi-based treatment targeting Hepatitis B virus
RNAi-based treatment for Hepatitis C genotypes
Proprietary system for efficient DNA vector delivery
Funding Insights of Nucleonics
Nucleonics has successfully raised a total of $51.9M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $2.7 million completed in October 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nucleonics
Nucleonics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Alnylam, Oxford Finance and Burrill and Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
A biotechnology venture capital firm investing in innovative science.
|
Locked | Locked | Locked |
Investor details for Nucleonics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nucleonics
Investment portfolio details for Nucleonics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nucleonics
Detailed financials for Nucleonics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nucleonics Comparisons
Peer comparison for Nucleonics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nucleonics
Nucleonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Denali Therapeutics, MiRagen and Avidity Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
Detailed competitors of Nucleonics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nucleonics
Complete news archive for Nucleonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nucleonics
Nucleonics was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Nucleonics is headquartered in Langhorne, United States. It is registered at Langhorne, Pennsylvania, United States.
Nucleonics is a funded company, having raised a total of $51.9M across 3 funding rounds to date.
Nucleonics was a clinical stage company focussed on developing RNAi therapeutics for viral and other diseases. It claims to include over 100 active patent filings, including 16 that have granted worldwide and 6 that have been granted in the U.S., Europe, or Japan. Its lead candidate NUC-B1000 is an RNAi-based therapy which was in phase 2 trials for Hepatitis-B. In December 2008, Alnylam acquired Nucelonics and its assets.
Nucleonics's top competitors include Moderna, Juno Therapeutics and Adaptive Biotechnologies.
Nucleonics offers Hepatitis B Therapeutic Program, Hepatitis C Therapeutic Program, and DNA Delivery Technology.
Nucleonics has 9 investors. Key investors include Alnylam, Oxford Finance, Burrill and Company, Quaker Partners Management, and SR One.